| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total non-operating expense, net | -4,137 | 1,603 | -1,531 | -579 |
| Loss before income taxes | -7,388 | 10,563 | -6,082 | -8,359 |
| Income tax (expense) benefit | 247 | -246 | 447 | -47 |
| Net loss | -7,635 | 10,809 | -6,529 | -8,312 |
| Unrealized gain related to available for sale securities, net | 190 | -93 | 75 | 459 |
| Comprehensive loss | -7,445 | 10,716 | -6,454 | -7,853 |
| Earnings (loss) per share, class a common stock- basic (in dollars per share) | - | 0.38 | -0.23 | -0.31 |
| Earnings (loss) per share, class a common stock- diluted (in dollars per share) | - | 0.36 | -0.23 | -0.31 |
| Weighted average shares outstanding of class a common stock - basic (in shares) | - | 28,579,704 | 28,147,948 | 27,095,986 |
| Weighted average shares outstanding of class a common stock - diluted (in shares) | - | 29,753,933 | 28,147,948 | 27,095,986 |
| Basic loss per share, class a common stock (in dollars per share) | -0.27 | - | - | - |
| Diluted loss per share, class a common stock (in dollars per share) | -0.27 | - | - | - |
| Weighted-average shares outstanding of class a common stock - basic (in shares) | 28,797,730 | - | - | - |
| Weighted-average shares outstanding of class a common stock - diluted (in shares) | 28,797,730 | - | - | - |
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)